pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
ASTRAZENECA · news · pharmadog
← back to ASTRAZENECA
News mentioning ASTRAZENECA
209
stories
18d
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
biospace
18d
BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
fiercebiotech
18d
After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
fiercebiotech
18d
5 companies advancing ATTR assets in the wake of Wainua’s fail
biospace
18d
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
18d
Recon: AstraZeneca, BMS discuss merger; FDA broadens indication for Novartis’ Pluvicto
raps
19d
AstraZeneca, Bristol Myers in talks about merger — report
endpoints
21d
Lilly and Resilience invest $750M in diabetes and obesity drug device supply
biospace
21d
Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchise
biospace
22d
Alnylam plunges as earnings deliver ‘one-two punch’
biopharma dive
22d
Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts
biospace
22d
J&J secures right to take the helm in up to $925M Sail CAR T pact
biospace
22d
J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout
fiercebiotech
23d
Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push
biopharma dive
23d
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
fiercebiotech
23d
STAT+: Pharmalittle: We’re reading about a fugitive who became a biotech exec, a hospital suing Lilly, and more
stat
23d
Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more
biospace
23d
Biotechs bring big launches and pharma rivalries into Q2 earnings period
biospace
24d
Webinar: Building the Intelligence Engine for Drug Discovery R&D Teams
biospace
24d
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
fiercebiotech
25d
FDA scientists question Capricor data; Legend CEO steps down
biopharma dive
25d
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
biospace
25d
AstraZeneca looks to AI to ease risk in late-stage trials, speed up filings
endpoints
25d
Updated: AstraZeneca foresees blockbuster sales for Claudin 18.2 ADC, but Ultomiris flops in rare disease
endpoints
25d
Denmark’s foundation‑fueled biotech boom redraws the Nordic map
biospace
25d
AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates
fiercebiotech
25d
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
25d
FDA has recommitted to adcomms—but to what end?
biospace
25d
Recon: WHO releases first interim list of medical device authorities; AstraZeneca using AI to hedge late-stage risks
raps
27d
Anthropic’s life science plans; Novartis CEO on China deals; and more
endpoints
← prev
page 3 of 7
next →
